Evaluation of cross-neutralizing antibodies in children infected with omicron sub-variants
Open Access
- 26 October 2023
- journal article
- letter
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 40, 100939
Abstract
No abstract availableFunding Information
- Chinese Academy of Sciences
- China Postdoctoral Science Foundation
- Youth Innovation Promotion Association of the Chinese Academy of Sciences (2020092)
- National Natural Science Foundation of China (82072289, 82222040)
This publication has 9 references indexed in Scilit:
- Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variantsCell Reports, 2023
- Protective effect of plasma neutralization from prior SARS-CoV-2 Omicron infection against BA.5 subvariant symptomatic reinfectionThe Lancet Regional Health - Western Pacific, 2023
- Omicron BQ.1 and BQ.1.1 escape neutralisation by omicron subvariant breakthrough infectionThe Lancet Infectious Diseases, 2022
- Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolutionNature, 2022
- Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariantsCell, 2022
- Lower risk of multi-system inflammatory syndrome in children (MIS-C) with the omicron variantThe Lancet Regional Health - Western Pacific, 2022
- Omicron SARS-CoV-2 Neutralization from Inactivated and ZF2001 VaccinesNew England Journal of Medicine, 2022
- Multisystem Inflammatory Syndrome in U.S. Children and AdolescentsNew England Journal of Medicine, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020